首頁 > 市場調查報告書 > 製藥

慢性黃斑癬市場規模、佔有率和成長分析：按療法、藥物類別、給藥途徑、疾病嚴重程度、分銷管道、最終用戶和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2102163

慢性黃斑癬市場規模、佔有率和成長分析：按療法、藥物類別、給藥途徑、疾病嚴重程度、分銷管道、最終用戶和地區分類－2026-2033年產業預測

Chronic Plaque Psoriasis Market Size, Share, and Growth Analysis, By Treatment Type, By Drug Class, By Route of Administration, By Disease Severity, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年07月17日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球慢性黃斑成形術市場價值為 295 億美元，預計到 2033 年將從 2025 年的 315.1 億美元成長到 534.2 億美元，預測期（2026-2033 年）的複合年成長率為 6.82%。

全球慢性斑疹成形術乾癬市場的特點是治療、診斷和患者支持服務方面的進步，旨在控制這種高發生率的自體免疫疾病。患者生活品質受到的顯著影響，加上醫療成本的不斷上漲，推動了對創新療法的需求。雖然局部皮質類固醇一直是傳統療法的主導，但生物製藥的出現實現了標靶免疫調節，提高了治療效果。生物相似藥的引入提高了治療的可及性和可負擔性，尤其是在開發中國家市場。投資者密切關注治療產品線的發展，尤其關注具有更高便利性和安全性的口服小分子藥物。口服Janus激酶抑制劑的遵守用藥提高正在影響保險覆蓋範圍，並加速其在專科醫療機構中的應用。製造商正在加大對聯合治療研發的投入，以確保永續的收入成長並鞏固其業務基礎。

全球慢性黃斑成形術市場成長要素

提高大眾和醫療專業人員的認知度對於早期發現慢性黃斑病變患者並及時啟動治療方案至關重要。這種積極主動的方法可以延緩疾病進展，提高患者的生活品質，並鼓勵患者積極參與醫療保健系統。隨著越來越多的人尋求治療，對有效療法的需求持續成長，推動市場擴張，因為醫療服務提供者正在尋求滿足不同患者需求的創新解決方案。此外，提高公眾認知度的宣傳活動可以提高患者的用藥依從性，並使醫生能夠開立更先進的療法，從而進一步促進全球市場的成長。

全球慢性黃斑成形術市場的限制因素

全球慢性黃斑成形術市場面臨嚴峻挑戰，先進療法的高昂費用為病患、保險公司和醫療系統帶來了沉重的經濟負擔。這種經濟負擔導致保險覆蓋範圍受限，並需要預先核准，最終限制了患者的就醫途徑，也阻礙了醫療服務提供者開立昂貴的治療方案。因此，創新療法的市場滲透速度緩慢。此外，預算限制往往導致人們傾向於選擇學名藥和低成本的替代療法，從而降低了對尖端療法的需求，並限制了製造商的商機。另外，出於成本效益的考慮，支付方會要求回扣，這進一步增加了複雜性，可能阻礙產品的推廣應用。

慢性黃斑成形術市場的全球趨勢

由於生物相似藥的興起，慢性黃斑成形術的全球市場正經歷重大變革，這些生物相似藥使有效的治療方法更容易獲得且價格更實惠。這些生物相似藥以更低的成本提供與現有生物製藥相當的療效，擴大了患者覆蓋範圍，並減輕了醫療保健預算的負擔。隨著支付方越來越支持這些替代療法，製藥公司正在加強研發力度，導致市場競爭加劇。這種競爭格局迫使生技藥品的先驅開發商透過提供新一代製劑和增值服務進行創新，最終為全球臨床醫生和患者提供更廣泛的治療選擇。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

AbbVie Inc
Amgen Inc
Johnson & Johnson Services Inc
Bristol Myers Squibb Company
Eli Lilly and Company
Novartis AG
UCB SA
Boehringer Ingelheim International GmbH
Sun Pharmaceutical Industries Ltd
Leo Pharma AS
Pfizer Inc
Sanofi SA
Merck & Co Inc
AstraZeneca plc
GlaxoSmithKline plc
Teva Pharmaceutical Industries Ltd
Viatris Inc
Sandoz International GmbH
Lupin Limited
Cipla Limited

結論與建議

簡介目錄

Product Code: SQMIG35I3379

Global Chronic Plaque Psoriasis Market size was valued at USD 29.5 Billion in 2024 and is poised to grow from USD 31.51 Billion in 2025 to USD 53.42 Billion by 2033, growing at a CAGR of 6.82% during the forecast period (2026-2033).

The global chronic plaque psoriasis market is marked by evolving therapies, diagnostics, and patient support services aimed at managing this prevalent autoimmune disease. The significant impact on patients' quality of life coupled with rising healthcare expenses drives demand for innovative treatments. While topical corticosteroids have traditionally dominated, biologics have introduced targeted immune modulation, enhancing therapeutic efficacy. The emergence of biosimilars has increased accessibility and affordability, particularly in developing markets. Investors are keenly observing advancements in treatment pipelines, especially as oral small molecules gain traction, offering improved convenience and safety. Enhanced adherence associated with oral Janus kinase inhibitors influences payer formularies, facilitating quicker adoption in specialty care. Manufacturers are increasingly investing in research and development of combination therapies to ensure sustained revenue growth and resilience.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Plaque Psoriasis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Chronic Plaque Psoriasis Market Segments Analysis

Global chronic plaque psoriasis market is segmented by treatment type, drug class, route of administration, disease severity, distribution channel, end user and region. Based on treatment type, the market is segmented into topical therapy, systemic therapy, biologic therapy and phototherapy. Based on drug class, the market is segmented into corticosteroids, vitamin D analogues, TNF-alpha inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors, PDE4 inhibitors, TYK2 inhibitors and others. Based on route of administration, the market is segmented into topical, oral and injectable. Based on disease severity, the market is segmented into mild, moderate and severe. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on end user, the market is segmented into hospitals, dermatology clinics, specialty centers and homecare settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Chronic Plaque Psoriasis Market

The heightened awareness among the public and healthcare professionals plays a crucial role in the early identification of chronic plaque psoriasis patients and the timely initiation of treatment plans. This proactive approach leads to a slower disease progression, improved quality of life, and greater patient involvement in the healthcare system. As more individuals seek treatment, the demand for effective therapeutic options continues to rise, driving market expansion as healthcare providers seek innovative solutions for diverse patient needs. Furthermore, educational initiatives enhance patient compliance and empower physicians to prescribe advanced treatment modalities, further contributing to the global market's growth trajectory.

Restraints in the Global Chronic Plaque Psoriasis Market

The Global Chronic Plaque Psoriasis market faces significant challenges due to the high costs associated with advanced therapies, which impose considerable financial strain on patients, insurers, and healthcare systems. This economic burden can lead to restrictive formulary placements and prior authorization requirements, ultimately limiting patient access and deterring healthcare providers from prescribing premium treatments. As a result, the penetration of innovative therapies into the market is slowed. Additionally, budget constraints often favor the use of generics or lower-cost alternatives, thereby diminishing the demand for cutting-edge solutions and restricting revenue opportunities for manufacturers. Affordability concerns also compel payers to seek rebates, introducing further complexities that may hinder product adoption.

Market Trends of the Global Chronic Plaque Psoriasis Market

The Global Chronic Plaque Psoriasis market is experiencing a significant transformation driven by the rise of biosimilars, which are making effective treatments more accessible and affordable. These biosimilars provide comparable efficacy to established biologics at reduced costs, thus broadening patient coverage and easing the strain on healthcare budgets. As payers increasingly endorse these alternatives, manufacturers are intensifying their development efforts, which, in turn, enhances market competition. This competitive landscape compels original biologic developers to innovate through next-generation formulations and additional value-added services, ultimately expanding treatment options available to clinicians and patients throughout the global market.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape

Global Chronic Plaque Psoriasis Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Topical Therapy
Systemic Therapy
Biologic Therapy
Phototherapy

Global Chronic Plaque Psoriasis Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Corticosteroids
Vitamin D Analogues
TNF-alpha Inhibitors
IL-17 Inhibitors
IL-23 Inhibitors
IL-12/23 Inhibitors
PDE4 Inhibitors
TYK2 Inhibitors
Others

Global Chronic Plaque Psoriasis Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Topical
Oral
Injectable

Global Chronic Plaque Psoriasis Market Size by Disease Severity & CAGR (2026-2033)

Market Overview
Mild
Moderate
Severe

Global Chronic Plaque Psoriasis Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Chronic Plaque Psoriasis Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Dermatology Clinics
Specialty Centers
Homecare Settings

Global Chronic Plaque Psoriasis Market Size & CAGR (2026-2033)

North America (Treatment Type, Drug Class, Route of Administration, Disease Severity, Distribution Channel, End User)
- US
- Canada
Europe (Treatment Type, Drug Class, Route of Administration, Disease Severity, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, Drug Class, Route of Administration, Disease Severity, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, Drug Class, Route of Administration, Disease Severity, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, Drug Class, Route of Administration, Disease Severity, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

AbbVie Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S A
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sun Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Leo Pharma A S
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments